anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
All children were randomized 2 groups based on a computer-generated random number. The main interventions were occurred in post anesthetic care unit (PACU). In the operating room, all patients received a standardized anesthetic regimen by one anesthetist. Sevoflurane was used for maintenance without any opioids. Before the end of the procedure, spontaneous respiratory was recovered. All the patients were given 1 mcg/kg fentanyl intravenous injection after the end of the procedure. The positive result was defined as spontaneous respiratory rate decreased more than 50%, the others were defined as negative result. The result of fentanyl test submitted to assistant, and prepared the rescue analgesic drugs according to this result. One group: positive result 10μg/kg morphine; negative result 50μg/kg morphine. Another group: all received 25μg/kg morphine .The trachea was extubated when patients were awake, and then transported to the PACU. Patients with a Children's Hospital of Eastern Ontario Pain Scale score\>6 received rescue analgesic drugs and observe respiratory morbidity in each group.
Exercise training is a key component of pulmonary rehabilitation. It has shown signifcant improvements in both exercise tolerance and quality of life in patients with COPD. The intensity of exercise training is of great importance to yield a true physiologic effect. However, in patients with severe COPD, exertional dyspnea and leg fatigue make it impossible for the patient to maintain intensity of training for enough time to achieve a physiologic training effect. NIV has been reported to be used as support for exercise to improve exercise tolerance and respiratory performances in patients with mild-to-severe COPD with inconsistent results. Evidence from previous studies have suggested that NIV with a single-limb circuit with Whisper Swivel II expiratory valve or Plateau exhalation valve assisted during exercise in patients with COPD caused CO2 rebreathing. CO2 rebreathing may have a negative impact on efficacy. Previous studies have proved that exercise tolerance was improved ventilated by NIV with a dual-limb circuit. In theory, NIV with a dual-limb circuit consists of one inhalation limb that introduces air into the patient's airways and one exhalation limb that leads exhaled gas outside of the airways, there is no risk of rebreathing. However, there was no report on whether there's no risk of rebreathing in COPD patients ventilated during exercise by a dual-limb circuit. Therefore, the aim of the study was to determine whether there was no CO2 rebreathing occurred assisted with NIV with dual-limb circuit in patients with stable severe COPD after exercise with exertional dyspnea.
<P>PROBLEM TO BE SOLVED: To obtain a new antipyretic and analgesic composition comprising ibuprofen as a principal drug and having antipyretic and analgesic effects, especially high analgesic effects and analgesic sustaining effects, and further to provide an excellent drug for common cold.  <P>SOLUTION: The antipyretic and analgesic agent is characterized by comprising ibuprofen, tranexamic acid and/or its salt and ascorbic acid and/or its salt. The antipyretic and analgesic agent preferably contains caffeine. Furthermore, the excellent drug for common cold can be obtained by formulating other active ingredients, e.g. an antitussive, an expectorant, an antihistaminic agent or a snot secretion inhibitor.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The present invention relates to a lipstick production method capable of preventing the formation of bubbles, which improves cost-effectiveness by omitting a preheating process, wherein lipsticks are produced by going through the following steps sequentially: a cover mold combining step (S10), a lipstick filling step (S30), a cover mold separation step (S50), a lipstick container combining step (S60), and a lipstick withdrawal step (S70). Specifically, before the lipstick filling step (S30), the lipstick production method further comprises a rubber mold expansion step (S20) which applies a vacuum pressure to a rubber mold (30) to form a gently curved surface on the inner side thereof that enables a lipstick material to fill more successfully without having bubbles therein. Furthermore, after the lipstick filling step (S30), the lipstick production method comprises a rubber mold recovery step (S40) which removes the vacuum pressure to allow the rubber mold (30) to recover its original shape, thereby producing the lipsticks. Accordingly, before filling the lipstick material, merely by applying a vacuum pressure to the rubber mold to form a gently curved surface therein that enables the lipstick material to fill therein more successfully, the present invention can prevent the formation of bubbles on the surface of the lipsticks. Hence, by eliminating a preheating process for preventing the formation of bubbles, the present invention serves to extend the lifetime of the rubber mold and enhance the gloss on the surface of the lipsticks, and can utilize rubber molds of various materials. Further, the present invention offers more economical advantages such as reducing the production time by simplifying the production process.
OBJECTIVE: There is evidence to suggest that early amniotomy during induction of labor is advantageous. However, following cervical ripening balloon removal, the cervix remains less effaced and the utility of amniotomy in this setting is less clear. We investigated whether cervical effacement at the time of amniotomy impacts outcomes among nulliparas undergoing induction of labor.
STUDY DESIGN: This was a secondary analysis of a prospective cohort of singleton, term, nulliparous patients at a tertiary care center undergoing induction of labor and amniotomy. The primary outcome was completion of the first stage of labor. Secondary outcomes were vaginal delivery and postpartum hemorrhage. Outcomes were compared between patients with cervical effacement ≤50% (low effacement) and >50% (high effacement) at time of amniotomy. Multivariable logistic regression was used calculate risk ratios (RR) to adjust for confounders including cervical dilation. Stratified analysis was performed in patients with cervical ripening balloon use. A post hoc sensitivity analysis was performed to further control for cervical dilation.
RESULTS: Of 1,256 patients, 365 (29%) underwent amniotomy at low effacement. Amniotomy at low effacement was associated with reduced likelihood of completing the first stage (aRR: 0.87 [95% confidence interval, CI: 0.78-0.95]) and vaginal delivery (aRR: 0.87 [95% CI: 0.77-0.96]). Although amniotomy at low effacement was associated with lower likelihood of completing the first stage in all-comers, those who had amniotomy performed at low effacement following cervical ripening balloon expulsion were at the highest risk (aRR: 0.84 [95% CI: 0.69-0.98], p for interaction = 0.04) In the post hoc sensitivity analysis, including patients who underwent amniotomy at 3- or 4-cm dilation, low cervical effacement remained associated with a lower likelihood of completing the first stage of labor.
CONCLUSION: Low cervical effacement at time of amniotomy, particularly following cervical ripening balloon expulsion, is associated with a lower likelihood of successful induction.
KEY POINTS: · Low cervical effacement at amniotomy was associated with lower rates of complete dilation.. · Effacement at amniotomy is especially important for patients who had a cervical ripening balloon.. · Providers should consider cervical effacement when timing amniotomy for nulliparous term patients..
INTRODUCTION: Coronavirus disease 2019 (COVID-19) can have symptoms like many neurological diseases, and one of the rare forms of these presentations is opsoclonus-myoclonus ataxia syndrome (OMAS). The pathogenesis of OMAS in adults has not been clearly elucidated and OMAS can be fatal.
CASE PRESENTATION: We present a 71-year-old male patient who was admitted to the emergency department with complaints of involuntary tremor-like movements in his hands, feet and mouth, and speech impediment for three days, and was followed up with COVID-19. The patient was diagnosed with OMAS and clonazepam treatment was started. He died three days later due to respiratory arrest. Our case is the first case diagnosed with COVID-19-associated OMAS in Turkey.
DISCUSSION: OMAS has no definitive treatment. Early diagnosis and initiation of corticosteroids and intravenous immunoglobulin (IVIG) therapy, if necessary, can be life-saving. In COVID-19 patients with unexplained clinical findings, awareness of different and rare diseases and a multidisciplinary approach has vital importance.
The present invention discloses a hypoglycmic-slimming bean which takes refined konjac starch and soluble fibre as main raw materials, and then, evening primrose oil, perilla seed oil and vitamin E are added to the raw materials to be made in the shape of a candy bean with a conventional method. The present invention provides an article which has a hypoglycmic function and an obesity inhibiting function, and also provides leisure food for special people who are sick with obesity or have the trend toward obesity. The hypoglycmic-slimming bean can not cause the people who eat the hypoglycmic-slimming bean (particularly the people which have the trend toward obesity) to generate adverse psychology. The present invention has the advantages of good taste and easy acceptance, and can meet the habit of liking eating snacks of the people who are sick with obesity, particularly the people who have the trend toward obesity. The present invention has the characteristic of generating good hypoglycmic effect and good obesity inbiting effect. The hypoglycmic-slimming bean can be eaten by the people who are sick with obesity, particularly the special people who have the trend toward obesity.
Control Usual care consists of brief verbal education and a drug pamphlet to all patients when starting an ARAT. There is no GA+M and no RSM at either site. Patients have access to a 24x7 oncology nursing line or a 24/7 pharmacy line.
Objective: Maladaptive daydreaming (MD) is a compulsive form of daydreaming that causes distress and functional impairment among tens of thousands of self-diagnosed sufferers. This is the first controlled treatment trial for MD. Method: The investigators built an internet-based self-help program for MD and tested the effectiveness of mindfulness and self-monitoring in improving control over MD, compared to internet-based support as usual (waiting-list group). Participants were randomly assigned to three groups and measured across three points in time (baseline, post-intervention, and 6 months follow-up). The investigators measured the change in daydreaming pathology (MDS-16), daydreaming frequency (DDFS), and daydreaming functioning (DWSAS), alongside changes in psychiatric symptoms (BSI), and intervention outcome (OQ). Changes in mindful attention and awareness skills, compliance with program requirements, and feedback to the program were also measured.
The invention belongs to the field of pharmacy, and relates to a novel application of a flavan compound in preparing anti-complement medicines. According to the invention, a modern pharmacological screening method is applied, and researches are carried out upon anti-complement active substances in plant medicines. According to the invention, the flavan compound is obtained by separation from an n-butanol extract of a commelinaceae plant commelina and an n-butanol extract of a polygonum plant fagopyrum. With an in-vitro complement activity evaluation test, it is verified that the compound has high inhibition effect upon classical pathway and alternative pathway of a complement system. The CH50 of the inhibition effect of the compound upon the classical pathway of the complement system is 0.13 +- 0.03-0.78 +- 0.06 mM, and the AP50 of the inhibition effect of the compound upon the alternative pathway of the complement system is 0.12 +- 0.01-1.00 +- 0.15 mM. The compound can be used for preparing anti-complement medicines.
Addition prods. of >=1 g of iodine and a water-insoluble hydrophilic polymer, which liberates the iodine slowly, are new. A typical compsn. contains 25-40% N-vinyl pyrrolidone copolymerised with 45-20% 2-ethylhexylacrylate, the remainder being iodine. This was made into intrauterine suppositories, each contg. 1 g of iodine. Larger doses of iodine may be given and treatment administered less frequency, due to the slow liberation of the iodine. There is no risk of residues passing into the milk, and fertility is not affected.
Sotalol (AF) can cause serious ventricular arrhythmias, primarily Torsade de Pointes (TdP) type ventricular tachycardia, a polymorphic ventricular tachycardia associated with QT interval prolongation. QT interval prolongation is directly related to the dose of sotalol (AF). Factors such as reduced creatinine clearance, gender (female) and larger doses increase the risk of TdP. The risk of TdP can be reduced by adjustment of the sotalol (AF) dose according to creatinine clearance and by monitoring the ECG for excessive increases in the QT interval.

Treatment with sotalol (AF) must therefore be started only in patients observed for a minimum of three days on their maintenance dose in a facility that can provide electrocardiographic monitoring and in the presence of personnel trained in the management of serious ventricular arrhythmias. Calculation of the creatinine clearance must precede administration of the first dose of sotalol (AF). For detailed instructions regarding dose selection, see DOSAGE AND ADMINISTRATION.
INTRODUCTION: Parallel to the worldwide increase in obesity, the epidemic of chronic liver disease is increasing also in pediatric population. Our aim is to provide a different outlook on the current screening confusion in pediatric non-alcoholic fatty liver disease (NAFLD) with the non-invasive vibration-controlled transient elastography (VCTE) method.
MATERIALS AND METHODS: This single-center, cross-sectional, comparative study was performed at the tertiary center, included 95 patients with obesity and 116 controls, both groups were 9-18 years of ages. VCTE examinations performed in all patients. The cut-off values for controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) were established by comparing the study and control groups.
RESULTS: The cut-off for CAP was determined as >236 dB/m when comparing the two groups. The AUC was 0.900 (95% CI, 0.851-0.937) and the diagnostic accuracy was 77.9% and 91.4% for sensitivity and specificity, respectively. The cut-off value for LSM >5 kPa was determined by comparison of the two groups. The AUC was 0.794 (95% CI, 0.733-0.846) and the diagnostic accuracies were 50.5% and 90.5% for sensitivity and specificity, respectively.
CONCLUSIONS: There is no benchmark method for screening pediatric NAFLD. However, VCTE is a promising method for screening pediatric NAFLD. It is accessible, repeatable and practical.
Patients will receive SCRI-huCAR19v1 in either Phase 1 or Phase II. As of 02/13/2020 this study cohort is permanently closed.
Systems and methods are disclosed for providing focused ultrasound treatment. A patient is screened to determine if focused ultrasound treatment is appropriate for the patient to treat a disorder. The patient is monitored to measure a plurality of wellness-related parameters for the patient and detect or predict an onset of symptoms associated with the disorder from the wellness-related parameters if focused ultrasound treatment has been determined to be appropriate. A personalized location for focused ultrasound treatment is determined for the patient according to at least one of the wellness-related parameters. At least one parameter associated with the focused ultrasound treatment is selected according to at least one of the wellness-related parameters. Focused ultrasound treatment is provided to the patient at the selected location using the selected at least one parameter. The p wellness-related parameters are measured after focused ultrasound treatment is provided to determine an effectiveness of the treatment.
HDGEC after clincial onset: TMS \>5, DCL = 4. Moderate stage of disease: TFC 7-10. No other major comorbidity.
Preterm infants are at high risk of stunting due to premature birth, insufficient intrauterine nutrient reserves, burden of various diseases after birth, and persistent nutrient liabilities. The growth retardation of premature infants at different developmental stages has an important impact on both short-term survival and long-term health. The growth and development data of premature infants during hospitalization and after discharge are very limited in foreign countries. Domestic researches on growth retardation of preterm infants only involve retrospective cross-sectional studies during hospitalization, and lack of prospective follow-up study data on growth and development data of premature infants during hospitalization and after discharge.

In this cohort, prospective clinical cohort study was used to establish a follow-up cohort of preterm infants with different gestational ages. The regular monitoring indexes of physical development and neuropsychological development of preterm infants from birth to 3 years after birth were collected. The influencing factors of preterm infants' development at different stages were recorded, and the high-risk factors leading to different stages of preterm infants' growth retardation were analyzed. In order to provide a strong scientific basis for the development evaluation and intervention of premature infants in China, a systematic and scientific clinical cohort study method was explored to improve the overall medical quality and medical level of the Department and further promote the development of the discipline.
The invention relates to the field of cosmetics, and particularly relates to an anti-allergy repair essence and a preparation method thereof. An anti-allergy repair essence, which mainly comprises: l-vitamin C, tea extract, citric acid, trehalose, dipotassium glycyrrhizinate and licorice extract. The content of the tea extract and the ginkgo leaf extract is not zero at the same time. The content of the levorotatory vitamin C is not less than 99.5 percent, the oligopeptide-1 is a tripeptide molecule, the sequence is GHK, and the content of the protein is not less than 1.63 mg/ml. The dipotassium glycyrrhizinate in the anti-allergy repair essence is an anti-allergy agent, can prevent histamine in skin from releasing, has the effects of detoxifying, disinfecting and resisting allergy, and has no side effect after long-term use. The Glycyrrhrizae radix extract contains glycyrrhizin as main effective component, and has effects in resisting allergy, inhibiting skin inflammation, and inhibiting proliferation of Staphylococcus aureus and Bacillus subtilis on skin. And can regulate the immunity of skin to external stimuli. Both are derived from natural plants, and have no side effects or toxicity.
The present invention relates to a bear bile powder eye drop with bear bile powder as raw material and a preparation method thereof. The bear bile powder eye drop of the present invention is prepared from refined bear bile powder, phosphate buffering agent, etc. The present invention has the advantage of simple and reasonable technology, and the bear bile powder eye drop has the action of inhibiting bacteria, resisting viruses, improving eyesight, etc. and is used for clearing away heat, calming the liver, improving eyesight and treating acute bacterial conjunctivitis and epidemic viral keratoconjunctivitis with liver fire, inflammation and heat damage to collaterals of eyes as symptoms. In addition, the bear bile powder eye drop treats symptoms of sore, red and swelling eyes, chemosis and hyperemia of bulbar conjunctiva, much gum in the eyes, sticky eyelids, photophobia and lacrimation. The total effective rate is more than 99%, the total excellence rate is more than 92%, and the bear bile powder eye drop has the characteristics of short course of treatment, high safety, good effect, etc.
BACKGROUND: Prenatal inflammation exposure (PIE) can increase the disease susceptibility in offspring such as lung cancer. Our purpose was to investigate the mechanisms of PIE on lung cancer.
METHODS: Prenatal BALB/c mice were exposed to lipopolysaccharide (LPS), and then, their offspring were intraperitoneally instilled with urethane to establish the two-stage lung cancer carcinogenesis model. At the 48 weeks of age, the offspring mice were killed and lung tissues were collected for HE, immunohistochemistry, immunofluorescence, and Luminex MAGPIX®-based assays. CD11b + F4/80 + tumor-associated macrophages (TAMs) were sorted out from lung tumor tissues by cell sorting technique. Flow cytometry was employed to evaluate the extent of M2-like polarization of TAMs and PD-L1 expression.
RESULTS: The offspring of PIE mice revealed more lung lesion changes, including atypical hyperplasia and intrapulmonary metastases. The number of lung nodules, lung organ index, and PCNA, MMP-9 and Vimentin positive cells in lung tissue of PIE group were higher than those of Control group. The increases of mRNA encoding M2 macrophage markers and cytokines in offspring of prenatal LPS-treated mice confirmed the induced effect of PIE on macrophage polarization. Additionally, PIE treatment increased the percentage of CD163 + CD206 + cells in the sorted TAMs. Importantly, endoplasmic reticulum (ER) stress-markers like GRP78/BIP and CHOP, p-IRE1α and XBP1s, and PD-L1 were up-regulated in TAMs from PIE group. Besides, we also observed that IRE1α inhibitor (KIRA6) reversed the M2-like TAMs polarization and metastasis induced by PIE.
CONCLUSIONS: IRE1α/XBP1-mediated M2-like TAMs polarization releases the pro-tumorigenic cytokines and PD-L1 expression, which may be the regulatory mechanism of accelerating lung cancer in offspring of mice undergoing PIE.
PURPOSE: A novel antibiotic activity compound and an antibiotic composition including thereof are provided to obstruct activity of Malonyl-CoA-acyl carrier protein transacylase(MCAT) and cell growth. CONSTITUTION: A novel antibiotic activity compound is represented by one of chemical formula 1 and 2. The compound obstructs activity of Malonyl-CoA-acyl carrier protein transacylase(MCAT). A pharmaceutical composition for preventing or treating infections by pathogens comprises the compound of the chemical formula 1 and 2, and a pharmaceutically acceptable carrier. The composition inhibits activity of microorganism lipogenesis. A stockfeed composition for prevention or treating infection includes the compound of the chemical formula 1 or 2 and a carrier which is acceptable in quellenkunde. An agricultural composition for preventing or treating infection includes the compound of the chemical formula 1 or 2 and a carrier which is acceptable in agricultural pharmacology.